The assessment of antiplatelet activity of aspirin among survivors of myocardial infarction treated with PCI in six months observation - Preliminary results;Ocena przeciwpłytkowego działania aspiryny wśród pacjentów po zawale serca leczonych PCI w obserwacji półrocznej - Wyniki wstepne

Polski Przeglad Kardiologiczny

Volumn 9, Issue 5, 2007, Pages 335-341

  Kamińska, Marta ^a   Osada, Joanna ^b   Dabrowska, Milena ^b   Kłoczko, Janusz ^c   Kramkowski, Karol ^c   Musiał, Włodzimierz J ^a  

^a Laboratory of Flowcytometry   (Poland)

^b Zaklad Diagnostyki Hematologicznej   (Poland)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

ASA resistance; Obesity; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CHOLESTEROL; COLLAGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEART INFARCTION; HUMAN; MALE; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SURVIVOR; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

EID: 38049123530     PISSN: 15075540     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Antiplatelet Trialists' Collaborabon: Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ, 1994, 308, 81-106.
2. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy the prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324, 71-86.
3. Van de Werf F., Ardissino D., Betriu A. i wsp.: Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardioiogy. Eur. Heart J., 2003, 24, 28-66.
4. Watala C., Golanski J., Pluta J. i wsp.: Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb. Res., 2004, 113, 101-113.
5. Friend M., Vucenik I., Miller M.: Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ, 2003, 326, 82-83.
6. Tamminen M., Lassila R., Westerbacka J. i wsp.: Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int. J. Obes. Relat. Metab. Disord., 2003, 27, 907-911.
7. Buchanan M.R., Schwartz L., Bourassa M. i wsp.: Results of the BRAT study - a pilot study investigating the possible signilicance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery surgery. Can. J. Cardiol., 2000, 16, 1385-1690.
8. Pulcinelle F.M., Pignatelli R, Celectini A. i wsp.: Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J. Am. Coll. Cardiol., 2004, 43, 979-984.
9. Cardinal D.C., Flower R.J.: The electronic aggregometer: a novel device for assessing platelet behavior in blood. J. Pharmacol. Methods, 1980, 3, 135-58.
10. Baj Z.: Wykorzystanie cytometrii przepływowej w badaniach płytek krwi. Cent. Eur. J. Immunol., 1996, 21, 119-127.
11. American Diabetes Association: Clinical Practice Recommendations 2006. Diabetes Care, 2006, 29, S1-S2.
12. Minuz P., Patrignani P., Gaino S. i wsp.: Determinants of Platelet Activation in Human Essential Hypertension. Hypertension, 2004, 43, 64.
13. Ferroni P., Basili S., Falco A. i wsp.: Oxidant stress and platelet activation in hypercholesterolemia. Antioxid. Redox Signal., 2004, 6, 747-756.
14. Davi G., Romano M., Mezzetti A. i wsp.: Increased Levels of Soluble P-Selectin in Hypercholesterolemic Patients. Circulation, 1998, 97, 953-957.
15. Ferroni P., Basili S., Davi G.: New insights in the pathogenesis of prothrombotic state associated with hypercholesterolemia. Recenti Prog. Med., 2004, 95, 169-178.
16. Davi G., Averna M., Catalano I. i wsp.: Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation, 1992, 85, 1792-1798.
17. McDonagh P.F., Hokama J.Y., Gale S.C. i wsp.: Chronic expression of platelet adhesion proteins is associated with severe ischemic heart disease in type 2 diabetic patients: Chronic platelet activation in diabetic heart patients. J. Diabetes Complications, 2003, 17, 269-278.
18. Santilli F, Davi G., Consoli A. i wsp.: Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J. Am. Coll. Cardlol., 2006, 47, 391-397.
19. Davi G., Gresele P., Violi F. i wsp.: Diabetes Mellitus, Hypercholesterolemia, and Hypertension but Not Vascular Disease Per Se Are Associated With Persistent Platelet Activation In Vivo Evidence Derived From the Study of Peripheral Arterial Disease. Circulation, 1997, 96, 69-75.
20. Davi G., Guagnano M.T., Ciabattoni G. i wsp.: Platelet activation in obese women: role of inflammation and oxidant stress. JAMA, 2002, 288, 2008-2014.
21. Sacco M., Pellegrini F., Roncaglioni M.C. i wsp.: PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care, 2003, 26, 3264-3272.
22. Trovati M., Anfossi G., Cavalot F. i wsp.: Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes, 1988, 37, 780-786.
23. Westerbacka J., Yki-Järvinen H., Turpeinen A. i wsp.: Inhibition of Platelet-Collagen Interaction An In Vivo Action of Insulin Abolished by Insulin Resistance in Obesity. Arterioscer. Thromb. Vasc. Biol., 2002, 22, 167.
24. Trovati M., Mularoni E.M., Burzacca S. i wsp.: Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes, 1995, 44, 1318-1322.
25. Anfossi G., Mularoni E.M., Burzacca S. i wsp.: Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care, 1998, 21, 121-126.
26. Huczek Z., Kochman J., Filipiak K.J. i wsp.: Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J. Am. Coll. Cardiol., 2005, 46, 284-290.